AI-powered self-service platform for all your sourcing decision needs across 1,200+ categories like Viral Vaccines.
Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.Schedule a Demo
The European Commission has approved a purchase agreement amendment for Valneva's inactivated COVID-19 vaccine.July 27, 2022
WuXi Vaccines Received Ireland Health Products Regulatory Authority's First GMP Certificate of QC Potency LabJuly 21, 2022
Vaccizone has chosen Exothera to handle the process development and GMP manufacturing of its SARSCoV2 vaccine, which is based on proprietary ASC technology.July 13, 2022
Become a Beroe LiVE.Ai™ Subscriber to receive proactive alerts on Viral VaccinesSchedule a Demo
Viral Vaccines Market Monitoring Dashboard
Understand the correlation between costs, margins, and prices impacting your category on a real time basis on Beroe LiVE.Ai™Schedule a Demo
Viral Vaccines Industry Benchmarks
The average annual savings achieved in Viral Vaccines category is 2.50%
The industry average payment terms in Viral Vaccines category for the current quarter is 90.0 days
Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™
Category Strategy and Flexibility
Price per Unit Competitiveness
Minimum Order Quality
The World’s first Digital Market Analyst
The World’s first Digital Market Analyst
Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions
Abi is now supercharged with GPT4 AI engine. Enjoy the ease of ChatGPT, now on Abi
Viral Vaccines market report transcript
Viral Vaccines Global Market Outlook
The global demand is expected to grow at approx. 7 percent CAGR through 2020–2027 and would reach approximately $ 58.4 Billion by the year 2024. 15-20% of the growth can be attributed to vaccine development and testing
Rise in prevalence of several infectious and non-infectious disease is promoting technological advancements in faster production of vaccines, and large number of international vaccination programs, government and non-government initiatives, and increase in demand for combined vaccine are responsible for boost in the market growth
Large CROs have been continuously expanding their supply base through acquisitions and partnerships to provide integrated services related to vaccine production
Global Market Size: Viral Vaccines
There is an increasing awareness of immunization and a inspiration to formulate strong vaccine pipeline and the increasing focus of the key pharmaceutical players to develop innovative vaccines. These factors are driving the market with a CAGR of 7 percent and is expected to reach $71.65 billion by the end of 2027.
The market dynamics of research chemistry can be understood from the demand–supply perspective
From the demand side, pharmaceutical companies are facing pipeline issues and outsourcing additional activities. This trend has led to the emergence of outsourcing of production services, with emerging nations like India and China becoming favorable destinations
The viral vaccine production function is highly outsourced to leverage technical expertise and specific therapeutic area skill set at CROs
Regional Market Share
It is easier to offshore more routine services, like Live-attenuated vaccine production and Subunit Vaccine production, to emerging regions, like India and China. However, services, like Toxiod Vaccines and Conjugated Vaccine Production that require strict regulatory guidelines, are mostly near shored to the developed markets
This is expected to change in the future with suppliers, like Wuxi Optec, building capabilities in technologies, like computer-aided drug development and identify potential drug candidates in lesser time. Such factors will expedite the drug development process
Cost Structure of Viral Vaccines
Cost for product development, equipment's and labor contributes a maximum of 65-70 percent of the overall agency base price, and comprises of direct cost (buying or manufacturing cost) and indirect cost (third-party engagement cost). Another factor is skilled labour cost, which differs widely, depending on the scope of the trials, location and the therapeutic area involved (e.g., average FTE cost depends upon the location and therapeutic area)
The viral vaccines market is primarily driven by the rising prevalence of infectious diseases, innovative technology in vaccine development, increased funding from governmental and international organizations, and the rising awareness on preventive care.
This overhead cost component includes fees for service and facilities, technology deployment/up gradation cost, and out-of-pocket cost
Contribution to overall agency cost solely depends on the type of trial and location of the manufacturing
Labor cost includes direct payroll cost and the cost of temporary players or third-party engagements
Labor cost will continue to increase (at an average rate of 2-3 percent) as vaccine production requires specialist attention, and will drive extensive third-party resource allocation
Discover the world of market intelligence and how it can elevate your business strategies.
Learn more about how market intelligence can enable informed decision-making, help identify growth opportunities, manage risks, and shape your business's strategic direction.